Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis
Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-a...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2001-04, Vol.8 (3), p.227-233 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 233 |
|---|---|
| container_issue | 3 |
| container_start_page | 227 |
| container_title | Annals of surgical oncology |
| container_volume | 8 |
| creator | Dolan, J T Miltenburg, D M Granchi, T S Miller, 3rd, C C Brunicardi, F C |
| description | Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer.
All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05.
Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with < or =2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone.
In patients with metastatic breast cancer, treatment with somatostatin analogues was associated with a tumor response of over 40% with few side effects. Best results were achieved when somatostatin analogues were given as first-line therapy. |
| doi_str_mv | 10.1007/s10434-001-0227-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_227347041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>931412241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-fc36e46e26712c15249219cf61726e82749bec69adc81806e7921b6f2befd7243</originalsourceid><addsrcrecordid>eNpFkFtLAzEQhYMotlZ_gC8SfI9mkmyy-yjFGxQEqc8hmya6pbupSYr235tewKcZzpwzHD6EroHeAaXqPgEVXBBKgVDGFPk9QWOoiiJkDadlp7ImDZPVCF2ktCw-xWl1jkYAHETDmzF6n0dncu-GjIPHvcsmZZM7i9uip4ytGayL-KfLXziF3uSwvw_YDGYVPjcuEWL2ObJTtqlLl-jMm1VyV8c5QR9Pj_PpC5m9Pb9OH2bEskpm4i2XTkjHpAJmoWKiYdBYL0Ex6WqmRNM6KxuzsDXUVDpV7q30rHV-oZjgE3R7-LuO4bsUyXoZNrGUSLrA4EJRAcUEB5ONIaXovF7Hrjdxq4HqHUR9gKgLHL2DqH9L5ub4eNP2bvGfOFLjf_OkbRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227347041</pqid></control><display><type>article</type><title>Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Dolan, J T ; Miltenburg, D M ; Granchi, T S ; Miller, 3rd, C C ; Brunicardi, F C</creator><creatorcontrib>Dolan, J T ; Miltenburg, D M ; Granchi, T S ; Miller, 3rd, C C ; Brunicardi, F C</creatorcontrib><description>Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer.
All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05.
Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with < or =2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone.
In patients with metastatic breast cancer, treatment with somatostatin analogues was associated with a tumor response of over 40% with few side effects. Best results were achieved when somatostatin analogues were given as first-line therapy.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/s10434-001-0227-x</identifier><identifier>PMID: 11314939</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Female ; Humans ; Insulin-Like Growth Factor I - drug effects ; Octreotide - adverse effects ; Octreotide - analogs & derivatives ; Octreotide - therapeutic use ; Peptides, Cyclic - adverse effects ; Peptides, Cyclic - therapeutic use ; Somatostatin - adverse effects ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Annals of surgical oncology, 2001-04, Vol.8 (3), p.227-233</ispartof><rights>The Society of Surgical Oncology, Inc. 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c256t-fc36e46e26712c15249219cf61726e82749bec69adc81806e7921b6f2befd7243</citedby><cites>FETCH-LOGICAL-c256t-fc36e46e26712c15249219cf61726e82749bec69adc81806e7921b6f2befd7243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11314939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dolan, J T</creatorcontrib><creatorcontrib>Miltenburg, D M</creatorcontrib><creatorcontrib>Granchi, T S</creatorcontrib><creatorcontrib>Miller, 3rd, C C</creatorcontrib><creatorcontrib>Brunicardi, F C</creatorcontrib><title>Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer.
All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05.
Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with < or =2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone.
In patients with metastatic breast cancer, treatment with somatostatin analogues was associated with a tumor response of over 40% with few side effects. Best results were achieved when somatostatin analogues were given as first-line therapy.</description><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - drug effects</subject><subject>Octreotide - adverse effects</subject><subject>Octreotide - analogs & derivatives</subject><subject>Octreotide - therapeutic use</subject><subject>Peptides, Cyclic - adverse effects</subject><subject>Peptides, Cyclic - therapeutic use</subject><subject>Somatostatin - adverse effects</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkFtLAzEQhYMotlZ_gC8SfI9mkmyy-yjFGxQEqc8hmya6pbupSYr235tewKcZzpwzHD6EroHeAaXqPgEVXBBKgVDGFPk9QWOoiiJkDadlp7ImDZPVCF2ktCw-xWl1jkYAHETDmzF6n0dncu-GjIPHvcsmZZM7i9uip4ytGayL-KfLXziF3uSwvw_YDGYVPjcuEWL2ObJTtqlLl-jMm1VyV8c5QR9Pj_PpC5m9Pb9OH2bEskpm4i2XTkjHpAJmoWKiYdBYL0Ex6WqmRNM6KxuzsDXUVDpV7q30rHV-oZjgE3R7-LuO4bsUyXoZNrGUSLrA4EJRAcUEB5ONIaXovF7Hrjdxq4HqHUR9gKgLHL2DqH9L5ub4eNP2bvGfOFLjf_OkbRg</recordid><startdate>200104</startdate><enddate>200104</enddate><creator>Dolan, J T</creator><creator>Miltenburg, D M</creator><creator>Granchi, T S</creator><creator>Miller, 3rd, C C</creator><creator>Brunicardi, F C</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200104</creationdate><title>Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis</title><author>Dolan, J T ; Miltenburg, D M ; Granchi, T S ; Miller, 3rd, C C ; Brunicardi, F C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-fc36e46e26712c15249219cf61726e82749bec69adc81806e7921b6f2befd7243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - drug effects</topic><topic>Octreotide - adverse effects</topic><topic>Octreotide - analogs & derivatives</topic><topic>Octreotide - therapeutic use</topic><topic>Peptides, Cyclic - adverse effects</topic><topic>Peptides, Cyclic - therapeutic use</topic><topic>Somatostatin - adverse effects</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dolan, J T</creatorcontrib><creatorcontrib>Miltenburg, D M</creatorcontrib><creatorcontrib>Granchi, T S</creatorcontrib><creatorcontrib>Miller, 3rd, C C</creatorcontrib><creatorcontrib>Brunicardi, F C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dolan, J T</au><au>Miltenburg, D M</au><au>Granchi, T S</au><au>Miller, 3rd, C C</au><au>Brunicardi, F C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2001-04</date><risdate>2001</risdate><volume>8</volume><issue>3</issue><spage>227</spage><epage>233</epage><pages>227-233</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer.
All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05.
Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with < or =2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone.
In patients with metastatic breast cancer, treatment with somatostatin analogues was associated with a tumor response of over 40% with few side effects. Best results were achieved when somatostatin analogues were given as first-line therapy.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11314939</pmid><doi>10.1007/s10434-001-0227-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2001-04, Vol.8 (3), p.227-233 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_journals_227347041 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Female Humans Insulin-Like Growth Factor I - drug effects Octreotide - adverse effects Octreotide - analogs & derivatives Octreotide - therapeutic use Peptides, Cyclic - adverse effects Peptides, Cyclic - therapeutic use Somatostatin - adverse effects Somatostatin - analogs & derivatives Somatostatin - therapeutic use Time Factors Treatment Outcome |
| title | Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A20%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20metastatic%20breast%20cancer%20with%20somatostatin%20analogues--a%20meta-analysis&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Dolan,%20J%20T&rft.date=2001-04&rft.volume=8&rft.issue=3&rft.spage=227&rft.epage=233&rft.pages=227-233&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/s10434-001-0227-x&rft_dat=%3Cproquest_cross%3E931412241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227347041&rft_id=info:pmid/11314939&rfr_iscdi=true |